FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000418578> ?p ?o ?g. }

• W3000418578 abstract "Objective: To evaluate the efficacy and safety of 2 infusions of eptinezumab for the preventive treatment of migraine in adults with chronic migraine (CM). Background: Eptinezumab, an anti-CGRP monoclonal antibody, selectively inhibits the CGRP ligand, which plays an important role in migraine pathophysiology. Design/Methods: Eligible patients (CM, ICHD-3β) were randomized to eptinezumab 100mg, 300mg, or placebo administered intravenously every 12 weeks (wks) for 2 infusions. The primary endpoint was the change from baseline in mean monthly migraine days (MMDs) over Wks1–12. Key secondary endpoints included: ≥75% migraine responder rates (RRs) over Wks1–4; ≥75% and ≥50% migraine RRs over Wks1–12. Results: Baseline mean MMDs were ~16.1 across treatment groups (N=1072). In 100mg-treated patients, changes from baseline in MMDs were −7.7 (p In 300mg-treated patients, changes from baseline in MMDs were −8.2 (p In placebo-treated patients, changes from baseline in MMDs were −5.6 and −6.1 over Months1–3 and Months4–6, respectively. The ≥75% migraine RRs were: 15.6% (Month1), 15.0% (Months1–3), and 22.7% (Months4–6). The ≥50% migraine RRs were: 39.3% (Months1–3) and 44.5% (Months4–6). Rates of treatment-emergent adverse event were similar between groups. Conclusions: Eptinezumab significantly reduced MMDs over 3 months, which was further improved through Month 6 following a second quarterly infusion. Migraine RRs were greater with eptinezumab vs placebo over 3 months and were sustained or increased through Month 6. The eptinezumab safety profile was consistent with previous trials. Disclosure: Dr. Kudrow has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder, Eli Lilly, Amgen, Promius and AOBiome. Dr. Kudrow has received research support from Amgen, Alder, Ely Lilly, Teva, Roche-Genentech, Allergan, Biohaven, UCB, and Viromed. Dr. Lipton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with American Academy of Neurology, Alder Biopharmaceuticals, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir Pharmaceuticals, Biohaven, Biovision, Boston Scientific, Dr. Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, and Vedanta. Dr. Lipton holds stock and/or stock options in Biohaven. Dr. Silberstein has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder Biopharmaceuticals, Allergan, Amgen, Avanir, eNeura, ElectroCore Medical, Labrys Biologics, Medscape, Medtronic, Neuralieve, NINDS, Pfizer, and Teva. Dr. Silberstein has received compensation for serving on the Board of Directors of eNeura and Biohaven. Dr. Silberstein has received royalty, license fees, or contractual rights payments from Biohaven. Dr. Silberstein holds stock and/or stock options in Biohaven which sponsored research in which Dr. Silberstein was involved as an investigator. Dr. Silberstein holds stock and/or stock options in Biohaven. Dr. Silberstein has received research support from Allergan, Amgen, Cumberland Pharmaceuticals, ElectroCore Medical, Labrys Biologics, Eli Lilly, Merz, and Troy Healthcare.. Dr. Cady has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder BioPharmaceuticals, Inc. Dr. Schaeffler has nothing to disclose. Dr. Biondi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder BioPharmaceuticals, Inc.. Dr. Biondi holds stock and/or stock options in Alder BioPharmaceuticals, Inc. Dr. Smith has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder. Dr. Smith holds stock and/or stock options in Alder." @default.
• W3000418578 created "2020-01-23" @default.
• W3000418578 creator A5000448269 @default.
• W3000418578 creator A5023730853 @default.
• W3000418578 creator A5039406215 @default.
• W3000418578 creator A5042860187 @default.
• W3000418578 creator A5045253087 @default.
• W3000418578 creator A5078913596 @default.
• W3000418578 creator A5084396069 @default.
• W3000418578 date "2019-04-09" @default.
• W3000418578 modified "2023-09-23" @default.
• W3000418578 title "Eptinezumab for Prevention of Chronic Migraine: Results of 2 Infusions in the Phase 3 PROMISE-2 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy–2) Trial (P2.10-006)" @default.
• W3000418578 hasPublicationYear "2019" @default.
• W3000418578 type Work @default.
• W3000418578 sameAs 3000418578 @default.
• W3000418578 citedByCount "1" @default.
• W3000418578 countsByYear W30004185782020 @default.
• W3000418578 crossrefType "journal-article" @default.
• W3000418578 hasAuthorship W3000418578A5000448269 @default.
• W3000418578 hasAuthorship W3000418578A5023730853 @default.
• W3000418578 hasAuthorship W3000418578A5039406215 @default.
• W3000418578 hasAuthorship W3000418578A5042860187 @default.
• W3000418578 hasAuthorship W3000418578A5045253087 @default.
• W3000418578 hasAuthorship W3000418578A5078913596 @default.
• W3000418578 hasAuthorship W3000418578A5084396069 @default.
• W3000418578 hasConcept C126322002 @default.
• W3000418578 hasConcept C142724271 @default.
• W3000418578 hasConcept C168563851 @default.
• W3000418578 hasConcept C197934379 @default.
• W3000418578 hasConcept C203092338 @default.
• W3000418578 hasConcept C204787440 @default.
• W3000418578 hasConcept C27081682 @default.
• W3000418578 hasConcept C2778541695 @default.
• W3000418578 hasConcept C2910587157 @default.
• W3000418578 hasConcept C3018359032 @default.
• W3000418578 hasConcept C42219234 @default.
• W3000418578 hasConcept C535046627 @default.
• W3000418578 hasConcept C71924100 @default.
• W3000418578 hasConceptScore W3000418578C126322002 @default.
• W3000418578 hasConceptScore W3000418578C142724271 @default.
• W3000418578 hasConceptScore W3000418578C168563851 @default.
• W3000418578 hasConceptScore W3000418578C197934379 @default.
• W3000418578 hasConceptScore W3000418578C203092338 @default.
• W3000418578 hasConceptScore W3000418578C204787440 @default.
• W3000418578 hasConceptScore W3000418578C27081682 @default.
• W3000418578 hasConceptScore W3000418578C2778541695 @default.
• W3000418578 hasConceptScore W3000418578C2910587157 @default.
• W3000418578 hasConceptScore W3000418578C3018359032 @default.
• W3000418578 hasConceptScore W3000418578C42219234 @default.
• W3000418578 hasConceptScore W3000418578C535046627 @default.
• W3000418578 hasConceptScore W3000418578C71924100 @default.
• W3000418578 hasOpenAccess W3000418578 @default.
• W3000418578 hasRelatedWork W2781760325 @default.
• W3000418578 hasRelatedWork W2789072256 @default.
• W3000418578 hasRelatedWork W2792852282 @default.
• W3000418578 hasRelatedWork W2805739889 @default.
• W3000418578 hasRelatedWork W2806335825 @default.
• W3000418578 hasRelatedWork W2811121788 @default.
• W3000418578 hasRelatedWork W2893615962 @default.
• W3000418578 hasRelatedWork W2897284151 @default.
• W3000418578 hasRelatedWork W2900030708 @default.
• W3000418578 hasRelatedWork W2901040310 @default.
• W3000418578 hasRelatedWork W2950025797 @default.
• W3000418578 hasRelatedWork W2982561889 @default.
• W3000418578 hasRelatedWork W3047736609 @default.
• W3000418578 hasRelatedWork W3093745937 @default.
• W3000418578 hasRelatedWork W3093820723 @default.
• W3000418578 hasRelatedWork W3095164195 @default.
• W3000418578 hasRelatedWork W3172467076 @default.
• W3000418578 hasRelatedWork W3174901842 @default.
• W3000418578 hasRelatedWork W3191369108 @default.
• W3000418578 hasRelatedWork W3203718780 @default.
• W3000418578 hasVolume "92" @default.
• W3000418578 isParatext "false" @default.
• W3000418578 isRetracted "false" @default.
• W3000418578 magId "3000418578" @default.
• W3000418578 workType "article" @default.